GLW:
Hello there - sorry you had to find us. The disorder that you are talking about is different than ITP which is what most of us have here. It's pretty rare for someone to actually have a diagnosed familial platelet disorder on the Forum. I don't see it very often and I've been here for 14 years. I don't know whether doctors don't look into it often enough or it truly is that rare, but it is a different scenario than what we are dealing with. I couldn't even tell you if the treatments are the same.
I did find this which may be helpful if you can get psat the medicalese. It is from 2004, so there may be updated info around. Blood Journal is a very credible site though.
"Familial platelet disorder with associated myeloid malignancy (OMIM: 601399 [OMIM] FPDMM). In 1996, a large kindred was reported with autosomal dominant thrombocytopenia and a striking predisposition for hematologic malignancy.22 In this family, the degree of thrombocytopenia was mild to moderate, and platelets had normal size and appearance. However, bleeding times were prolonged and an aspirin-like defect in aggregation studies was observed.22 Linkage analysis narrowed the affected gene to an interval on human chromosome 21q22.1-22.2.22
Etiology. The abnormal gene has been identified as AML1, also known as CBFA2 and RUNX1. FPDMM has now been associated with either deletion of a single allele (eg, haploinsufficiency) or point mutations of AML1 that abrogate DNA binding of the runt domain.23,24 Evidence suggests that mutated forms of AML-1 that can heterodimerize with PEBP2{beta}/CBF{beta} in a dominant-negative manner have a higher rate of hematologic malignancy than gene deletion.24 Confirming its role in hematopoiesis, disruption of the cbfa2 gene in mice caused failure of definitive hematopoiesis and lethal hemorrhage during embryonic days 11.5 to 12.5.25 Interestingly, hemizygous deletion of one cbfa2 allele resulted in lower erythroid and myeloid colonies (CFU-MK and platelet counts were not reported).25 Suppression of runx1 in zebrafish results in failure of hematopoiesis as well as angiogenesis, suggesting a critical role for the gene in the hemangioblast.26 It is not clear why, in humans, the heterozygous loss of AML1 function as a transcription factor and tumor suppressor during hematopoiesis should result in a phenotype that is primarily thrombocytopenia.
Special circumstances: related stem cell transplantation in FPDMM. Because of the high incidence of myeloid leukemia at a relatively young age (< 60 years), it is likely that many affected individuals will eventually undergo hematopoietic stem cell transplantation. Unless the clinician is aware of the potential for FPDMM, mild thrombocytopenia in an HLA-matched sibling might be overlooked. There has already been at least one reported case of a transplant from a sibling in which both the donor and recipient subsequently developed donor-derived leukemia. If a mutation in AML1 has been identified in a patient with FDP/AML, then potential sibling donors should be screened for this mutation, even if the platelet count is normal."
bloodjournal.hematologylibrary.org/content/103/2/390.full.html